
Novavax Inc. (NASDAQ:NVAX) shares are trading lower Tuesday after the company acknowledged to Reuters that it has completed delivery of only about 10 million doses of its COVID-19 vaccine.
This number comes in much lower than the 2 billion doses that were expected to be delivered around the world.